SIESTA study: do cancer hormone treatments steal your sleep?
NCT ID NCT04543799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how hormone treatments for prostate and breast cancer affect sleep quality. Researchers will monitor 60 patients using sleep tests, activity trackers, and questionnaires before treatment starts, then again at 6 and 12 months. The goal is to understand if these treatments cause sleep problems and whether the type of cancer or treatment matters.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2020
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
i) Patients with localized, locally advanced or metastatic hormone-sensitive prostate cancer receiving standard of care treatment (including radiotherapy with or without androgen-deprivation treatment (ADT) or ADT alone +/- androgen receptor targeted agent) dependent on disease stage ii) Patients with full-resected early (stage I-III) epithelial BC, ductal carcinoma in situ or lobular carcinoma in situ, without evidence of residual disease
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for prostate cancer patients: * Written infor med consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures * Histologically proven adenocarcinoma of the prostate * Eastern Cooperative Oncology Group performance status 0-2 * Adult male patient \> 18 years of age, no upper age limit * Localized prostate cancer, locally advanced hormone-sensitive prostate cancer (HSPC) or metastatic hormone-sensitive prostate cancer (mHSPC) * ADT recipients are required to be scheduled to start ADT as standard of care (SOC) for metastatic or locally advanced prostate cancer * Scheduled to receive ADT treatment as SOC for \> 6 months in combination with radiotherapy or oral AR-targeted systemic treatment as prescribed by the treating physician or radiotherapy alone Exclusion Criteria for prostate cancer patients: * Histology with predominant small cell prostate cancer * Any previous treatment with ADT or oral AR-targeted agent (exception for short course anti-androgens - disease flare) * Have not received systemic treatment for any other cancer within the last 12 months * Active secondary malignancy that requires systemic therapy * Any clear contraindications present against treatment with ADT * Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \>15 at baseline * Body mass index (BMI) \> 35 at baseline * Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline * Severe cardiovascular disease or severe cardiovascular event \< 6 months * History of stroke or other neurologic chronic illnesses \< 6 months * Have demonstrated impaired mental status * History of brain tumours, presence of brain metastases or previous cranial irradiation * Night shift workers * Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening * Unhealthy sleep hygiene * Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline * Present diagnosis of depression or psychiatric illness pharmacologically treated * Diagnosis of insomnia and chronic intake of hypnotic medication at baseline * Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake \> 25 mg/day) * Any diagnosed condition that causes known sleep disturbance Inclusion criteria for breast cancer patients * Written informed consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures * Women with full-resected early (stage I-III) epithelial BC, ductal carcinoma in situ or lobular carcinoma in situ, without evidence of residual disease * Eastern Cooperative Oncology Group performance status 0-2 * Adult female patient ≥ 18 years of age, no upper age limit * Proven postmenopausal status (defined by absence of menstruation for at least 6 months and/or level of estradiol \<40 pg/ml, or bilateral oophorectomy or ovarian irradiation for suppression of ovarian function) Exclusion criteria for breast cancer patients * Non-epithelial BC or BC with mixed epithelial and non-epithelial histology * Previous chemotherapy at any time, in treatment with ET at not standard dosage * Have received systemic treatment for any other cancer within the last 12 months * Active secondary malignancy that requires systemic therapy * Presence of sleep apnea syndrome, Apnea Hypopnea Index (AHI) \>15 at baseline * Body mass index (BMI) \> 35 at baseline * Severe respiratory disorders (asthma, Chronic obstructive pulmonary disease) at baseline * Severe cardiovascular disease or severe cardiovascular event \< 6 months * History of stroke or other neurologic chronic illnesses \< 6 months * Have demonstrated impaired mental status * History of brain tumours, presence of brain metastases or previous cranial irradiation * Night shift workers * Excessive lifestyle: massive coffee intake at night, regular excessive cigarette and alcohol consumption in the evening * Unhealthy sleep hygiene * Nocturia (the urgent need to urinate more than 2 times during the main sleep period at night) at baseline * Present diagnosis of depression or psychiatric illness pharmacologically treated * Diagnosis of insomnia and chronic intake of hypnotic medication at baseline * Chronic intake of medications that are known to induce sleep disturbance (antihistamines of first generation, cortisone intake \> 25 mg/day) or any diagnosed condition that causes known sleep disturbance
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IOSI
RECRUITINGBellinzona, 6500, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Radioactive missile aims at prostate cancer that spread
- Can High-Risk breast cancer patients skip an extra radiation boost?
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?
- Can a new PET tracer spot hidden prostate cancer spread?